HURA Stock Forecast & Price Target

TuHURA Biosciences is supported by a pipeline aimed at overcoming resistance to current immunotherapies, with IFx-2.0 targeting primary checkpoint-inhibitor resistance and next-generation programs focused on myeloid biology and ADC platforms. Recent Phase 1b/2a data are encouraging, as all three evaluable patients achieved durable partial responses through the protocol-specified six-month assessment, which may partially de-risk the ongoing randomized Phase 3 trial and broaden the addressable MCC population, given that about 30% present with deep-seated tumors. Additional upside comes from management’s progress across IFx-2.0, TBS-2025, and ADC programs, including FDA-written responses after IND submission and timelines for a Phase 1b/2 study in relapsed/refractory NPM1-mutated AML.

TuHURA Biosciences is viewed negatively because its core value proposition remains highly speculative while clinical development risk is substantial, as its assets may fail to show sufficient efficacy or safety in current or future trials. Financially, the company reported $8.7M of OpEx in 2Q26, only $1.0M of cash and equivalents, and had drawn $5.7M of the available $50M Parkview credit facility as of June 2026, signaling tight liquidity and dependence on external funding. Beyond that, regulatory uncertainty, intense competition from better-resourced biotechnology and pharmaceutical peers, and the likelihood of additional equity financing create meaningful dilution risk for existing shareholders.